Abstract:Objective To investigate the clinical eff ic acy and safety of double filtration plasmapheresis (DFPP) combined with daclizum ab(Dac)in the treatment of sensitized recipients of cadaver kidney transplanta tion. Methods Panel reactive antibody (PRA) was examined with ELISA before transplantation.A total of 113 sensitized recipients (PRA20% ) were assigned to 2 groups according to study intervention: group A ( n =72) receiving DFPP and group B ( n =41) as controls.Group A was subdivided into 2 groups:group A1 ( n =44) was treated by DFPP alone and group A2 ( n =28) was treated by DFPP plus Dac.The incidence rates of HAR,AR,adverse reaction,patie nt/kidney survival,kidney function were observed. All the patients obtained a fo llow-up ≥12 months. Results In 72 patients of group A ,the level of PRA decreased from (60.5±17.7)% to (19.3±11.2)%,with a mean of (41.2±16.9)% ( P 0.0001).In Group A,the incidence rates of HAR and AR we re significantly lower (1.4% and 27.8%) than those in group B (9.8% and 43.9%, P 0.05).One person-year survival was 98.6% in group A and 90.2% in gr oup B ( P 0.05),with 1 kidney-year survival of 94.4% in group A and 78.0 % in group B ( P 0.05).In subgroup A1 and A2,the incidence rates of HAR w as 2.3% and 0% ( P 0.05);those of AR were 36.4% and 14.3%,respectively ( P 0.05);the patient/kidney survival rates of 1 year were 97.8%/93.2% and 100%/96.4%,respectively ( P 0.05).No difference in infection episodes an d adverse events between group A and PRA-negative recipients, the same as those between group A1 and A2. Conclusions DFPP can decrease the level of PRA significantly before transplantation by selectively eliminating the sensitive antibody,especially when combined with Dac,which can make sensiti zed recipients get the chance of transplanting and further reduce the incidence of AR.The patient/kidney survival rates of 1 year are satisfactory.Being well to lerated by the sensitized patients,treatment of DFPP combined with Dac is safe a nd effective.

Renal transplantation across the donor-specific antibody barrier: Graft outcome and cancer risk after desensitization therapy

Study on variation characteristics of anti-donor specific antibodies in different species of sensitized mice after skin transplantation

Impact of Alloantibody Strength in Crossmatch Negative DSA Positive Kidney Transplantation

A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy

Survival in Sensitized Lung Transplant Recipients With Perioperative Desensitization

Double Filtration Plasmapheresis Combined with Daclizumab in the Treatment for Sensitized Recipients of Cadaver Kidney Transplantation

Understanding the Significance of Low-Level Preformed Donor-Specific Anti-Hla Antibodies in Renal Transplant Patients.

Low Incidence of Acute Antibody-Mediated Rejection after HLA Desensitization in Living Donor Kidney Transplant Recipients

The detrimental effect of donor-specific antibodies is irrespective of its level in highly-immunized living donor kidney transplant recipients: A case-control series

Abo-Incompatible Living Kidney Transplantation

ABO‐incompatible Living Kidney Transplantation

A personalised delisting strategy enables successful kidney transplantation in highly sensitised patients with preformed donor‐specific anti HLA antibodies

Effect of sensitization on primary cadaveric renal allograft survival following deliberate unrelated blood transfusions

Influence of de novo donor-specific antibody on early renal allograft function recovery.

Management of the sensitized pediatric renal transplant candidate

Anti-HLA Class II Antibodies Are the Most Resistant to Desensitization in Crossmatch-positive Living-donor Kidney Transplantations: A Patient Series

[Negative effects of donor specific anti-HLA antibody on poor hematopoietic recovery in patients with hematological diseases receiving haploidentical stem cell transplantation and rituximab for desensitization].

Highly Sensitized Candidates Remain at Risk for Microvascular Inflammation Even When Donor-specific Antibody Is Avoided: A Matched Cohort Study

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome

Pre-transplant donor specific antibodies in ABO incompatible kidney transplantation – data from the Swiss transplant cohort study

Double Filtration Plasmapheresis Combined with Rituximab for Donor-Specific Antibody Desensitization in Haploidentical Haematopoietic Stem Cell Transplantation.